Barbara Pro - Concepedia

Author

Barbara Pro

The University of Texas MD Anderson Cancer Center

Also Known As

B Pro, B. Pro, Barbara Pro, Daniel Persky, Pro, B.

421

Publications

17.1K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Northwestern University Memorial Sloan Kettering Cancer Center Washington University in St. Louis City of Hope

About

Barbara Pro is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pathology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	40	2.1K
2	Health Sciences	9	9	270
3	Cellular Therapies	4	4	158
4	Blood Transplantation	2	2	146
5	Cell Biology	2	2	97

Barbara Pro

156

Publications

14.6K

Citations

H-Index

Page 1

	Year	Citations
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study Barbara Pro, Ranjana H. Advani, Pauline Brice, Journal of Clinical Oncology	2012	979
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project Massimo Federico, Monica Bellei, Luigi Marcheselli, Journal of Clinical Oncology	2009	736
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, The Lancet	2018	707
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy Bertrand Coiffier, Barbara Pro, H. Miles Prince, Journal of Clinical Oncology	2012	664
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown, Journal of Clinical Oncology	2011	630
High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine Jorge Romaguera, Luis Fayad, Maria Alma Rodriguez, Journal of Clinical Oncology	2005	557
Adenocarcinoma of the small bowel Bouthaina S. Dabaja, Dima Suki, Barbara Pro, Cancer	2004	534
Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma André Goy, Anas Younes, Peter McLaughlin, Journal of Clinical Oncology	2004	526
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins Catherine M. Bollard, Stephen Gottschalk, Vicky Torrano, Journal of Clinical Oncology	2013	491
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma Jorge Romaguera, L. Jeffrey Medeiros, Frederick Hagemeister, Cancer	2003	264

Page 1